COVID-19. COVID-19,virus identified
Conditions
Interventions
Intervention 1: Intervention group: Receive 0.5 mg of colchicine until the third day and 12 days later one mg plus standard treatment including 200 mg hydroxychloroquine daily. Intervention 2: Control
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: - Age 18 to 70 years - Detection of COVID-19 in the last 24 to 48 hours - Candidate for hospitalization (o2sat 24 or Pao2 / Fio2 <300) - COVID-19 patients hospitalized with hospital indications according to the guideline of the country that has pulmonary infiltration in CT scan -Not being pregnant and not becoming pregnant until 30 days after the end of the study - No consumption of colchicine during the last week ( due to the half-life of 20-40 hours of the drug) - Outpatients with pulmonary infiltration on CT scan
Exclusion criteria
Exclusion criteria: Patients with a history of Crohn or Ulcerative colitis, diarrhea, or chronic malabsorption Neuromuscular diseases GFR less than 30 ml per minute History of cirrhosis, hepatitis and severe liver disease Patients receiving chemotherapy for cancer Patients currently taking colchicine for other uses, such as gout or Mediterranean fever Patients with a history of allergic reactions or allergies to colchicine Pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -Clinical symptoms including fever, cough, shortness of breath. Timepoint: The first, third, seventh, fourteenth and 6-8 days after entering the study. Method of measurement: questionnaire.;Pulmonary infiltration findings on CT scan. Timepoint: Two weeks later and 6-8 weeks later. Method of measurement: CT-scan.;O2sat at the time of hospitalization and discharge. Timepoint: The first, third, seventh, fourteenth and 6-8 days after entering the study. Method of measurement: Pulse Oximeter.;Laboratory symptoms (ESR, CRP, NLR, LDH, ferritin, D-dimer, CBC diff). Timepoint: Hospitalization time and discharge time. Method of measurement: Blood test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Need hospitalization in icu. Timepoint: The first, third, seventh, fourteenth and 6-8 days after entering the study. Method of measurement: questionnaire.;Mortality. Timepoint: The first, third, seventh, fourteenth and 6-8 days after entering the study. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNadia Soltani Gerdefaramarzi
Yazd University of Medical Sciences
Outcome results
None listed